Liporaxel (Paclitaxel Oral Solution) – Breast Cancer | HongKong DengYue Medicine

  • Generic Name/Brand Name: ​Paclitaxel / Liporaxel®
  • Indications: Breast cancer
  • Dosage Form: ​Oral solution
  • Specification: 300 mg × 1 vial/box
Category: Tag:

Paclitaxel Oral Solution Application Scope

Paclitaxel Oral Solution is an oral formulation of paclitaxel developed to improve patient convenience and compliance. It is mainly indicated for the treatment of breast cancer, gastric cancer, non-small cell lung cancer, and ovarian cancer, offering a non-intravenous alternative for patients requiring long-term therapy.

liporaxel paclitaxel oral solution
liporaxel paclitaxel oral solution

Paclitaxel Oral Solution Characteristics

  • Ingredients: Paclitaxel Oral Solution

  • Properties:​ Clear to slightly opalescent solution

  • Packaging Specification:​ 300 mg × 1 vial/box

  • Storage:​ Store at 15–25°C, protect from light

  • Expiry Date: 24 months

  • Executive Standard: ​In-house standard

  • Approval Number: Imported Drug Registration No. H20190023

  • Date of Revision: November 2022

  • Manufacturer: Daehwa Pharmaceutical Co., Ltd. (South Korea)

Guidelines for the Use of Liporaxel

  • Dosage and Administration:

    • Recommended Dose: 200 mg/m² once daily (or per regimen)

    • Administration: Oral, taken on an empty stomach with water

    • Missed Dose:​ Take as soon as remembered unless close to next dose; do not double dose

  • Adverse Reactions:

    • Common Adverse Reactions: Nausea, vomiting, diarrhea, alopecia, fatigue, peripheral neuropathy

    • Serious Adverse Reactions: Myelosuppression, severe hypersensitivity reactions, hepatotoxicity, severe infections

  • Contraindications:

    • Hypersensitivity to paclitaxel or excipients

    • Severe baseline neutropenia or thrombocytopenia

    • Pregnancy and breastfeeding

  • Precautions:

    • Regular blood counts and liver function monitoring are required

    • Use with caution in patients with impaired hepatic function.

    • Risk of severe allergic reactions—premedication may be required.

Paclitaxel Oral Solution Interactions

  • Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase paclitaxel exposure.

  • Concomitant use with CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce efficacy.

  • Concomitant use with cisplatin or doxorubicin may increase the risk of toxicity.

  • Monitor closely when used with immunosuppressants or anticoagulants.

 

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  •  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.
Contact Us
Contact Form Demo